Ginkgo Bioworks’ SPAC Success Is Good News for These Hedge Funds

The biotech company had a strong first day of trading and is so far bucking the trend of underperformance for recently merged special purpose acquisition companies.

September 20, 2021

Twitter
LinkedIn
Pinterest
Tumblr
Copy
Link copied
Print
Email

A Ginkgo Bioworks facility in Boston. (Scott Eisen/Bloomberg) — A Ginkgo Bioworks facility in Boston.

Good news for the slumbering SPAC market.

Shares of Ginkgo Bioworks got off to a strong start on the company’s first day of trading, rising more than 6 percent to close at $12.15 a share after the company completed its merger with the special purpose acquisition company Soaring Eagle Acquisition Corp.

This

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.